ECTRIMS 2017: Mark Freedman discusses recent developments and unmet needs in MS.

Mark Freedman discusses recent developments and unmet needs in MS.

Mark Freedman has received honoraria or consultation fees from Bayer Healthcare, Biogen-Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis and Teva Canada Innovation. He is a member of the following company advisory boards, board of directors or other similar group for Bayer Healthcare, Biogen-Idec, Hoffman La-Roche, Merck Serono, Novartis, Opexa and Sanofi-Aventis. He is a participant in Genzyme’s company-sponsored speaker’s bureau.